Oncology Nursing Drug Handbook Downloads & RevenueOncology Nursing Drug Handbook · App Store
Not in any tracked top chart right now.
Updated 7 Nov 2026 · rankings refresh through the day
DeveloperSkyscape Medpresso Inc
CategoryMedical
PriceFree
Released
Rating★ 4.8 (4)
Version5.8.5
Age rating17+
First seen by us
7 Nov 2026
Oncology Nursing Drug Handbook update history & changes
Last change · 3 events since 26 Nov 2017Full timeline ↓Full timeline · 3 events
- 🆕Oncology Nursing Drug Handbook first spotted by AppInsiderUnited States (found via similar)
- 📦Oncology Nursing Drug Handbook version 5.8.5- Minor Bug Fixes
- 🆕Oncology Nursing Drug Handbook released on the App Store
Collected from the stores by AppInsider since we first spotted the app. Dates are when we saw each change.
Rating
4.8 ★
4 ratings
Measured
Oncology Nursing Drug Handbook on the App Store
App details
App ID
1298511926
Publisher
Skyscape Medpresso Inc
On the store since
Nov 2017
8 years on the store
Minimum OS
iOS 13.0+
iPhone 6s and later
Devices
iPhone · iPad
Universal purchase
Content rating
17+
1 content note below
Languages
1
EN
Size
157 MB
Also listed in
Education
Content notesFrequent/Intense Medical/Treatment Information
Where it ranks now
Every top chart it appears in across 30 countries.
| Country | Charts | Rank |
|---|---|---|
| Not charting right now. | ||
Ratings
App Store, worldwide.
Rating
4.8 ★
4 ratings
Measured
Ratings
4
Measured
About Oncology Nursing Drug Handbook
"Try before you buy" - Download the FREE App, which includes sample content. An in-App purchase is required to unlock all content.
Created especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential resource provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.
Key Features
* Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
* Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
* Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
* Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
* New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)
No internet connection is required to access the content after the initial download. Find information quickly using powerful SmartSearch technology. Search part of term for those hard to spell medical terms.
Content licensed from printed ISBN 10: 1284171329
Content licensed from printed ISBN 13: 978-1284171327
SUBSCRIPTION :
Please choose an auto renewable subscription plan to receive content access & continuous updates. Your subscription automatically renews as per your plan, so you always have the latest content.
Yearly auto-renew
Created especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential resource provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.
Key Features
* Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
* Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
* Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
* Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
* New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)
No internet connection is required to access the content after the initial download. Find information quickly using powerful SmartSearch technology. Search part of term for those hard to spell medical terms.
Content licensed from printed ISBN 10: 1284171329
Content licensed from printed ISBN 13: 978-1284171327
SUBSCRIPTION :
Please choose an auto renewable subscription plan to receive content access & continuous updates. Your subscription automatically renews as per your plan, so you always have the latest content.
Yearly auto-renew
Latest updates
5.8.5
- Minor Bug Fixes